January 1, 2011
CardioDx Blood-Based Gene Expression Test Honored As One Of TIME Magazine's Top Ten Medical Breakthroughs of 2010

CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced that Corus™ CAD, the company’s blood-based gene expression test, has been honored as one of TIME Magazine’s Top Ten Medical Breakthroughs of 2010.

Corus CAD is the first and only clinically validated blood-based test to help clinicians confidently identify which of their stable symptomatic patients are likely to need further assessment for obstructive coronary artery disease.
“We agree that we are in the midst of one of the most exciting areas of medicine today, and we’re pleased that the Corus CAD gene expression test has been recognized by both The Wall Street Journal, with a Technology Innovation Award earlier this year, and by TIME Magazine – two venerable American publications,” said David Levison, chief executive officer of CardioDx.

Corus CAD delivers valuable information to cardiologists making decisions about which patients require advanced imaging or potential catheterization, and to primary care clinicians deciding which patients need a specialist referral. These decisions are increasingly important as clinical and regulatory communities recognize the need to reduce radiation exposure from medical imaging.

A study published in the March 11, 2010 issue of the New England Journal of Medicine found that in nearly 400,000 patients who underwent elective invasive angiographic procedures, 62% were found to have no obstructive coronary artery blockage. The study authors concluded that current modalities for identifying which patients should undergo elective invasive coronary angiography to diagnose coronary artery disease have limitations, and that better methods are needed for patient risk stratification.